Ioanna S.
- Country
- Greece
- Department
- Hematology Dept. BMT Unit
Research Overview
- A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
- Phase I Study of Iberdomide and CC-98282 in Combination with R-CHOP21 for Untreated Aggressive B-Cell Lymphoma
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 252 of 429 partner sites.
Specializations
Multiple Myeloma and Plasma Cell Disorders
Clinical research activity is strongly centered on multiple myeloma, including newly diagnosed, relapsed or refractory, high-risk, and transplant-ineligible disease, as well as smoldering multiple myeloma and plasma cell leukemia. The work also extends to treatment resistance, extramedullary disease, and post-transplant disease control.
- Relapsed and refractory multiple myeloma
- Newly diagnosed multiple myeloma
- High-risk smoldering multiple myeloma
- Plasma cell myeloma and plasma cell leukemia
Therapeutic interest includes immunotherapy, bispecific antibodies, CD38-directed treatment, proteasome inhibitor-based regimens, and approaches aimed at improving minimal residual disease clearance and long-term disease control.
Hematologic Malignancies and Lymphoma
Her portfolio includes a broad spectrum of hematologic cancers, especially diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, and myelodysplastic syndrome. Research also covers aggressive and relapsed/refractory lymphoma subtypes.
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- Acute myeloid leukemia and myelodysplastic syndrome
Key therapeutic domains include monoclonal antibodies, cell-directed immune therapies, B-cell malignancy treatment strategies, and novel combinations for refractory disease.
Thoracic Oncology and Solid Tumors
Another major focus is lung cancer, with activity across non-small cell lung cancer, small cell lung cancer, and molecularly defined subgroups such as EGFR-mutated, ALK-positive, RET fusion-positive, and KRAS G12C-mutated disease. The research landscape also includes breast cancer, gastric cancer, urothelial carcinoma, melanoma, pancreatic cancer, and colon cancer.
- Non-small cell lung cancer
- KRAS G12C-mutated solid tumors
- Breast cancer and melanoma
- Urothelial, gastric, and colorectal cancer
Therapeutic interests include targeted therapy, checkpoint inhibition, antibody-drug conjugates, and perioperative or adjuvant cancer treatment strategies.
Pulmonary Disease, Asthma, and Infectious Complications
Her research also covers respiratory medicine and infection-related conditions, including chronic obstructive pulmonary disease, severe asthma, idiopathic pulmonary fibrosis, bronchiectasis, cystic fibrosis, and pulmonary sarcoidosis. Infectious disease topics include sepsis, candidemia, hospital-acquired pneumonia, and recurrent Clostridioides difficile infection.
- Chronic obstructive pulmonary disease
- Severe asthma
- Idiopathic pulmonary fibrosis
- Sepsis and candidemia
Therapeutic emphasis includes anti-inflammatory treatment, antimicrobial therapy, and interventions for progressive lung disease and infection-associated complications.
Immune-Mediated, Renal, and Thrombotic Disorders
Her clinical trial activity includes immune thrombocytopenia, thrombotic thrombocytopenic purpura, paroxysmal nocturnal hemoglobinuria, myelofibrosis, chronic kidney disease, IgA nephropathy, membranoproliferative glomerulonephritis, and systemic lupus erythematosus. Cardiovascular and metabolic conditions such as heart failure, atrial fibrillation, hypertension, and type 2 diabetes also appear within the trial portfolio.
- Immune thrombocytopenia and thrombotic thrombocytopenic purpura
- Paroxysmal nocturnal hemoglobinuria
- Chronic kidney disease and IgA nephropathy
- Myelofibrosis and systemic lupus erythematosus
Therapeutic interest spans immune modulation, complement-mediated disease, renal protection, and management of thrombotic microangiopathy and related hematologic complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.